Jiangsu Chongli Biological Technologies Co., Ltd.: Intends to transfer controlling stake in subsidiary and passively provide financial support.

Morning Bio announced that its wholly-owned subsidiary, Hebei Morning Pharma, plans to transfer the 97.5% equity of Morning Tianrun Pharmaceutical it holds based on the book value of Morning Tianrun Pharmaceutical as of July 31, 2025 to Sichuan Tongsheng Biopharmaceutical Co., Ltd. After the transfer is completed, Morning Tianrun Pharmaceutical will no longer be included in the company's consolidated financial statements. As of July 31, 2025, the company provided a loan balance of 70.7824 million yuan to Morning Tianrun Pharmaceutical.